-
Story
Five Questions with Reshema Kemps-Polanco, Novartis US Chief Commercial Officer -
Story
Novartis in San Diego: A Quarter Century of R&D Innovation -
Story
Designing for the Future: The Next Era of Biomedical Research in San Diego -
Media Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Media Release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
-
Media Release
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
-
Media Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Media Release
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
-
Media Release
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
-
Story
Introducing the GARAGE by iLab: Behind the Scenes at Our New Innovation Hub -
Story
How We’re Reimagining Cancer Care for the Next Generation Patient -
Media Release
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline